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AbstrACt
Introduction Electronic cigarettes (EC) mainly with 
nicotine content are widely used worldwide. Although 
the number of publications about its use is increasing 
exponentially, evidence-based, unbiased, conclusive, head-
to-head comparisons about its efficacy and safety as an 
aid for smoking cessation are lacking.
Methods and analysis Design: randomised, placebo and 
reference treatment-controlled, multicentre, double-blind, 
double-dummy, parallel-group trial. Participants: smokers 
smoking at least 10 cigarettes/day in the past year and 
motivated to quit, aged 18–70 years. Interventions: (A) 
EC without nicotine (ECwoN) plus placebo tablets of 
varenicline administered by oral route: placebo condition, 
(B) EC with nicotine (ECwN) plus placebo tablets of 
varenicline: ECwN condition. Voltage regulated EC will 
be used with liquid containing 12 mg/mL of nicotine for 
ad libitum use. Flavour: blond tobacco. (C) Reference: 
ECwoN plus 0.5 mg varenicline tablets: varenicline 
condition. Varenicline administered according to the 
marketing authorisationauthorisation. Treatment duration: 
1 week+3 months. Primary outcome: continuous smoking 
abstinence rate (CAR) (abstinence from conventional/
combustible cigarettes) during the last 4 weeks (weeks 
9–12) of the treatment period defined as self-report of 
no smoking during the previous 2 weeks and expired air 
carbon monoxide ≤8 at visit 4 at week 10 after target quit 
date (TQD), that is, 11 weeks after treatment initiation 
AND at visit 5, week 12 after TQD, that is, 13 weeks after 
treatment initiation. Secondary outcomes: safety profile; 
point prevalence abstinence rate; CAR confirmed by 
urinary anabasine concentration; changes in cigarettes/
day consumption; craving for tobacco and withdrawal 
symptoms with respect of baseline.
Ethics and dissemination The ethics committee approval 
was obtained on 17 April 2018. All data collected about 
the study participants will be anonymised. Investigators 
will communicate trial results to participants, health 
authorities, healthcare professionals, the public and other 
relevant groups without any publication restrictions.
trial registration number NCT03630614; Pre-results.
IntroduCtIon
Tobacco use kills >5 million people per year 
worldwide. Among the five greatest risk factors 
for mortality, it is the single most preventable 
cause of death.1 It reduces life expectancy 
by 9–15 years.2–4 Implementation of tobacco 
control strategies, including smoking cessa-
tion behavioural and pharmacological treat-
ments, avoided 8 million premature deaths in 
the USA between 1964 and 2012.5 Smoking 
cessation before the age of 40 reduces the risk 
of death compared with continued smoking 
by 90%.3 
Tobacco is used in its combustible forms: 
cigarettes, cigarillos, pipes, cigars, shisha, or 
as smokeless tobacco: oral snuff, snus. The 
most widely used form is cigarettes. As of 
today, alternative nicotine delivery systems 
strengths and limitations of this study
 ► Randomised, head-to-head comparison, reference 
and placebo-controlled, double-blind, double-dum-
my smoking cessation efficacy and safety trial.
 ► Power sufficient to conclude about superiority of 
electronic cigarette with nicotine over electron-
ic cigarette without nicotine and non-inferiority of 
electronic cigarette with nicotine compared with 
varenicline.
 ► Ad libitum electronic cigarette use mimicking con-
ventional cigarette use.
 ► Only one, fixed-dose e-liquid nicotine concentration 
and one e-liquid flavour are used.
 ► A rigorous randomised controlled trial is prioritised 
over a pragmatic, everyday life trial, more likely to 
demonstrate convincingly efficacy and safety.
 ► However, this can reduce the generalisability of the 
results to everyday population use.
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(ANDS) such as electronic cigarettes (EC), Juul and heat-
not-burn/heated tobacco systems containing tobacco. 
These ANDS are used either for recreational purposes or 
with the intent to quit smoking.
Among ANDS, the most studied are EC. However as of 
today, their benefit/risk ratio as an aid for smoking cessa-
tion is not established with confidence.
EC are diverse battery-powered devices to produce an 
aerosol. The battery heats a resistance that allows aero-
solisation of the liquid called ‘e-liquid’ which contains 
humectants (propylene glycol and/or glycerin) along 
with flavourings and may or may not contain nicotine. The 
European Union (EU) Tobacco Product Directive limits 
the nicotine content to 20 mg/mL; requires products to 
be child and tamper proof; requires health warnings, 
instructions for use, information on addictiveness and 
toxicity to appear on the packaging; bans promotional 
elements on packaging; requires all substances contained 
in the product and information on the product’s nicotine 
content to be listed.6
The EU Directive has been transposed in France on 
19 May 2016.7
As of today, ECs are consumer products and sold 
outside the healthcare system. In France, pharmacies are 
prohibited to sell them.
Exposure to tobacco-related carcinogens and toxins 
are substantially lower among long-term EC users than 
among cigarette smokers or dual (EC+cigarettes) users 
and similar to that found among long-term nicotine 
replacement therapy (NRT) users.8 Substantial evidence 
shows that during EC use exposure to potentially toxic 
substances is lower compared with combustible/conven-
tional cigarette smoking.9
Last-generation EC deliver more nicotine than first-gen-
eration and second-generation EC. Venous plasma nico-
tine concentrations after 65 min use are up to 48.1 ng/mL 
in experienced and 31.4 ng/mL in naïve users and the 
mean venous plasma nicotine concentrations are close to 
those observed with conventional cigarettes.9–12
To the best of our knowledge, there is no published 
report on arterial plasma nicotine concentration with 
EC or nicotinic acetyl choline receptor occupancy in the 
brain while using EC with nicotine.
EC reduce desire/craving to smoke and withdrawal 
symptoms,13–16 main predictors of successful quit.
EC as an aid to quit smoking conventional cigarettes
Observational cohorts provided conflicting results as an 
aid to quit smoking17–19 and will not be mentioned further. 
Observational studies provide lower level of evidence (for 
various reasons) than randomised, controlled, double-
blind trials, therefore results are difficult to compare 
adequately.
Two randomised trials assessing the EC for smoking 
cessation20 21 and two meta-analyses of these two 
trials22 23 have been published. Caponnetto et al21 (Effi-
Ciency and Safety of an eLectronic cigAreTte [ECLAT] 
trial) randomised 300 smokers, not intended to quit 
into 3 groups: EC disposable cartridge containing 7.2 mg 
(n=100), 5.4 mg (n=100) and no nicotine (n=100) were 
used. Intent-to-treat (ITT) analysis of the main outcome 
did not show significant differences between groups. 
Bullen et al20 (A Study of Cessation using Electronic 
Nicotine Devices [ASCEND] trial) randomised smokers 
wanting to quit: 289 to receive nicotine containing EC, 
295 to receive 21 mg/24 hours nicotine patches and 73 
to receive EC without nicotine. Cartridges of nicotine EC 
contained 10–16 mg nicotine/mL. The treatment dura-
tion was 12 weeks and the main outcome measure was 
continuous abstinence at 6 months after quit date defined 
as ‘self-reported abstinence over the whole follow-up 
period, allowing ≤5 cigarettes in total’ and verified at 6 
months by a measure of expired air carbon monoxide 
(CO) (<10 ppm). All participants were referred to a 
quit line for support. The main outcome measure did 
not show statistically significant difference: 7.3%, 5.8%, 
4.1% in the nicotine EC, nicotine patch and placebo 
EC groups, respectively (ITT analysis). Serious adverse 
event  (SAE) was observed in 19.7% of the participants in 
the nicotine EC, 11.3% in the nicotine patch and 13.9% 
in the placebo EC group.
A Cochrane review of EC for smoking cessation and 
reduction has been published in 201422 and updated 
in 2016.23 The quality of evidence (Grading of Recom-
mendations Assessment, Development and Evaluation 
[GRADE] system) rated the evidence as low or very low 
because of the low (n=2) number of trials. Pooling data of 
these two trials, the authors report a relative risk (RR) of 
2.29, 95% CI 1.05 to 4.96 for abstinence rate at 6 months. 
Analysis of the same two trials20 21 did not confirm these 
results.17
A major randomised pragmatic but open trial has 
recently been published (30 January 2019).24 Smokers 
attending UK National Service stop-smoking services 
(n=886) were randomised to receive NRT for 3 months 
or a 1 month EC pack with liquid containing 18 mg/mL 
of nicotine. Both treatments could be used further at 
the discretion of the participants. The primary outcome 
measure of sustained abstinence at 1 year showed 18% 
in the EC and 9.9% abstinence in the NRT group (RR: 
1.82, 95 % CI: 1.30 to 2.58). More respiratory SAEs were 
observed in the EC than in the NRT group (5 vs 1). Inci-
dence of cough and phlegm were lower in the EC than in 
the NRT group. However, no SAEs occurred in either arm 
that were considered to be related to study treatment.
There is a general consensus that high-quality, large-
scale randomised studies are needed.9 25 The current trial 
is intended to fulfil this requirement.
objECtIvEs
Primary objective
To assess the therapeutic efficacy and safety of EC with 
nicotine for smoking cessation. EC containing nico-
tine to EC not containing nicotine (placebo) and to 
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varenicline, as a reference drug for smoking cessation, 
will be compared.
trial design
This will be a randomised, placebo-controlled, multi-
centre, double-blind, double-dummy, parallel groups, 
phase III type trial.
Included participants will be randomly assigned to one 
of the three groups:
A. Control group: EC without nicotine (ECwoN) plus 
placebo tablets of varenicline: placebo condition.
B. Experimental group: EC with nicotine (ECwN) plus 
placebo tablets of varenicline: ECwN condition.
C. Reference group: ECwoN plus varenicline tablets: 
varenicline condition with a randomisation ratio of 
A:B:C=1:3:3.
Each participant will use an EC and takes two tablets 
twice per day.
setting
This national trial will involve smoking cessation clinics 
of both academic and community hospitals. Twelve study 
sites and 16 co-investigators agreed to participate and 
committed to recruit and follow-up smokers for the trial. 
Individuals are eligible to be a co-investigator if they are 
medical doctors, having obtained a postgraduate diploma 
in addictive and/or tobacco-related disorders. The list of 
study sites can be obtained from the principal investigator.
PArtICIPAnts
Eligibility criteria
Inclusion criteria
1. Smokers smoking at least 10 cigarettes/day (factory 
made or roll-your-own) in the past year.
2. Aged 18–70 years.
3. Motivated to quit, defined as a score >5 on a visual rat-
ing scale ranging from 0 (not motivated at all) to 10 
(extremely motivated).
4. Signed written informed consent.
5. Understanding and speaking French.
6. Women of childbearing age can be included if they use 
an effective contraceptive method: either hormonal 
contraception or an intrauterine device started at least 
1 month before the first research visit.
7. Individual affiliated to a health insurance system.
8. Previous failure of NRT for smoking cessation.
Exclusion criteria
1. Any unstable disease condition within the last 3 months 
defined by the investigator as major change in 
symptoms or treatments such as recent myocardial 
infarction, unstable or worsening angina, severe car-
diac arrhythmia, unstable or uncontrolled arterial 
hypertension, recent stroke, cerebrovascular disease, 
obliterative peripheral arterial disease, cardiac insuf-
ficiency, diabetes, hyperthyroidism, pheochromocy-
toma, severe hepatic insufficiency, history of seizures, 
severe depression, chronic obstructive pulmonary 
disease (COPD).
2. Any life-threatening condition with life expectancy of 
<3 months.
3. Alcohol use disorder defined as a score ≥10 on the 
Alcohol Use Disorders Identification Test (AUDIT)-C 
questionnaire (see below).
4. Abuse of or dependence on illegal drugs in the last 6 
months revealed by medical history.
5. Regular use of tobacco products other than cigarettes.
6. Current or previous (last 6 months) use of EC.
7. Pregnant women.
8. Breastfeeding women.
9. Protected adults.
10. Current or past 3 months participation in another in-
terventional research.
11. Current or past 3 months use of smoking cessation 
medication such as varenicline, bupropion, NRTs.
12. Known lactose intolerance (placebo tablets contain 
lactose).
13. Hypersensitivity to the active substance or to any of 
the excipients.
14. Known severe renal failure.
Patient and public involvement
Patients or public were not involved in the conception 
and writing of this protocol. Study results will be dissem-
inated individually to all study participants if requested.
IntErvEntIons
Investigational product 1: EC with nicotine or EC placebo
EC exists in two forms: liquid containing nicotine or with 
liquid not containing nicotine.
Nicotine content in EC can vary in the EU between 0 and 
19.9 mg/mL. Third-generation and fourth-generation EC 
allow the user to change voltage and airflow leading to 
individualised nicotine delivery and dose adaptation.
A call for application by EC companies has been 
launched by the sponsor twice in 2017 and 2018 (no 
candidate in 2017).
Some major requirements for applications are listed 
here:
 ► EC liquid containing 0 and 12 mg/mL of nicotine;
 ► Regular and reported control of nicotine’s concentra-
tion in EC liquid by batches;
 ► Tobacco flavour;
 ► Long shelf life;
 ► Detailed information about constituents;
 ► Highly purified nicotine.
Packaging: active or placebo bottles of e-liquid will be 
provided blinded as unidentifiable bottles. Each blinded 
box package will contain ten 10 mL bottles of e-liquids for 
1 month.
In the current study, the ECwN group will use EC 
liquids containing 12 mg/mL of nicotine. e-Liquids will 
be allowed to be used ad libitum and because nicotine 
delivery can be adjusted according to the user’s need, 
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all participants would adjust their individual nicotine 
dose by varying the voltage of their EC, by varying puff 
frequency, puff volume and depth of inhalation similarly 
as they are doing (or used to do) with conventional ciga-
rettes. A recent paper by Soar et al26 demonstrates that 
over a 12-month period EC users maintained their nico-
tine intake, as measured by saliva cotinine concentration, 
possibly through self-titration.
justification of the nicotine concentration
We consider, based on previous studies, that one ciga-
rette contains approximately 1 mg of nicotine, thus 10 
cigarettes contain approximately 10 mg of nicotine.27 28 
Nicotine’s bioavailability when inhaled in cigarette smoke 
is 90%–95%; it is plausible that the bioavailability of nico-
tine of the aerosol delivered by an EC is lower. In the 
current research protocol, the use of e-liquid of 12 mg/
mL of nicotine may, thus, correspond approximately 
to 10 cigarettes. The randomised, placebo-controlled 
study (nicotine—placebo: double blind) against nico-
tine patch (open label) used in the nicotine EC arm 
10–16 mg/mL e-liquid concentration.20 Abstinence rate 
was not different between EC with nicotine versus EC 
with placebo (double-blind comparison) on the main 
outcome measure. It was raised that this negative result is 
due to the low bioavailability of nicotine delivered by the 
EC used dating back to 2012. More recent studies using 
tank system EC provide plasma nicotine concentrations 
higher than earlier studies using EC of 2012–2014.12
Dawkins et al29 assessed 6 and 24 mg/mL nicotine 
e-liquid concentrations in a self-titration/self-admin-
istration design. Plasma nicotine concentrations were 
higher with the 24 mg/mL nicotine liquid than with the 
6 mg/mL nicotine liquid. However, reduction in craving 
for cigarettes and withdrawal symptoms were similar. 
Compensatory puffing occurred with the 6 mg/mL nico-
tine concentration, puff number, puff duration and liquid 
consumption were higher with the low than with the high 
nicotine concentration liquid. There were no statistically 
significant differences between conditions in self-re-
ported craving, withdrawal symptoms, satisfaction, throat 
hit or adverse effects (AEs). However, the blood nicotine 
concentration was higher at 60 min with the 24 mg/mL 
than with the 6 mg/mL liquid: 43.57 (SD 34.78), 22.03 
(SD 16.19) ng/mL. Thus, EC users compensate low nico-
tine liquid concentration by increasing puff topography 
characteristics to increase nicotine uptake. This compen-
satory puffing is similar as with conventional cigarettes.
We can, thus, conclude that an intermediary concen-
tration of nicotine would be optimal: plasma nicotine 
concentrations sufficiently high leading to a sufficient 
craving reduction. The chosen e-liquid concentration of 
12 mg/mL takes also into account the standard dose-re-
sponse relationship (6–12–24 mg/mL).
Only one flavour will be used to reduce variability of 
treatment response according to a preferred flavour. We 
chose the blond tobacco flavour with which all smokers 
can be familiar, which is less likely to be aversive among 
adults and the most sold when initiating EC use.
EC device
Mini iStick kit (20 W) Eleaf, clearomiser: GS Air M with 
resistance of 1.5 ohm. To keep the blinding, the clear-
omiser’s Pyrex window is of grey colour not allowing to 
distinguish the colouration of the e-liquid containing 
nicotine.
Liquid for EC is manufactured by GAIATREND SARL 
(https://www. gaiatrend. fr/ fr/).
Counselling about the use of EC
All participants will be delivered a short manual and a 
video specifically developed for this study explaining the 
use of EC. At each visit, participants receive verbal coun-
selling about the use of the EC device and answers to their 
questions about handling the EC device. Investigators 
are trained at the first Investigators’ meeting to provide 
straightforward counselling about EC use.
Investigational product 2 (reference drug): varenicline 0.50 mg and 
its placebo
Varenicline and not NRT has been chosen for this study 
as the reference drug because:
i. Varenicline is associated with the highest level of 
abstinence rate among the three available smok-
ing cessation medications with marketing authori-
sation (bupropion, NRT, varenicline)30 31 (but its 
efficacy is similar to that of combined (short-act-
ing+long-acting) NRT32). Varenicline is, therefore, 
a better comparator for a new therapeutic interven-
tion for which we aim to demonstrate a therapeutic 
efficacy as high as the best available single medica-
tion treatment.
ii. Identical placebo tablets for varenicline can easily be 
manufactured and none of the placebo NRT forms 
are available. Manufacturers of NRT products do not 
have any more corresponding placebos and manu-
facturing identical placebos by an external company 
may increase the likelihood of non-identical place-
bos. Moreover, purchasing both identical placebos 
along with active NRT products manufactured by a 
company that do not have the marketing licence for 
NRT may introduce a major uncertainty by raising 
the question: Does the NRT product have the same 
bioavailability as the original, licensed NRT prod-
uct? Uncertainty about the active NRT product’s bio-
availability may compromise the validity of the trial’s 
results.
iii. Blinding of tablets administered by oral route is more 
convenient than blinding of NRT such as transder-
mal patches, gums, lozenges, inhaler or buccal spray.
Varenicline (Champix) 0.5 mg is presented as a capsu-
lar-shaped, biconvex, white film-coated tablet. The tablets 
are held under a phial of 56 tablets.
Varenicline has been purchased at Pfizer, France.
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List of excipients
Core tablets: cellulose, microcrystalline, calcium 
hydrogen phosphate anhydrous, croscarmellose sodium 
silica, colloidal anhydrous, magnesium stearate.
Film coating: hypromellose titanium dioxide (E171) 
macrogols triacetin.
Placebo and active tablets are strictly similar. Placebo 
tablets of varenicline have been manufactured, packaged 
and labelled by a pharmaceutical subcontractor according 
to the Good Manufacturing Practices and under the 
responsibility and supervision of Agence générale des 
équipements et produits de santé (AGEPS).
The dose regiment of varenicline/placebo follows 
varenicline’s monograph:
Day 1 to day 3: one tablet of 0.5 mg/placebo in the 
morning.
Day 4 to day 7: 1 tablet of 0.5 mg/placebo morning and 
the evening.
From day 8 until end of treatment: 1 mg morning and 
evening that is, two 0.5 mg/placebo tablets morning and 
evening. The number of tablets per day can be modified 
at the discretion of the investigator if a better control of 
AEs is needed.
EC and tablets are started 1 week before the target 
quit date (TQD) to stop smoking and followed up for 3 
months after TQD.
behavioural counselling for smoking cessation
Brief behavioural smoking cessation counselling for all 
participants is administered at all visits by the investiga-
tors specialised in smoking cessation. It is based on the 
national guidelines for smoking cessation.33
Criteria for discontinuing or modifying allocated interventions
Any participant can withdraw from participating in the 
research at any time and for any reason.
The investigator can end a subject's participation in 
the research for any reason that affects the partici-
pant's safety or which would be in the participant's best 
interests but not because of non-abstinence from ciga-
rettes after TQD.
In case of loss to follow-up, the investigator should 
make all efforts to reach the participant and collect the 
reason of loss to follow-up and information about his/
her safety data.
In case of pregnancy, despite the mandatory contra-
ception, the participant will exit the trial and will be 
followed up until delivery.
The case report form must list the various reasons for 
ending participation in the research:
 ► Adverse event/reaction;
 ► Other medical problem;
 ► Participant's personal reasons;
 ► Explicit withdrawal of consent.
If a participant leaves the research prematurely or with-
draws consent, any data collected prior to the date of 
premature exit can be used.
Methods for monitoring compliance with the treatments
Study medication compliance at visits 1 through 5 will be 
assessed with the questions:
A. Did you use the electronic cigarette?
 – Every day
 – Approximately every other day
 – Twice a week
 – Less than twice a week.
B. Did you take your tablets?
 – Every day
 – Approximately every other day
 – Twice a week
 – Less than twice a week.
Accountability of returned EC bottles and tablet vials 
will allow approximating EC liquid’s and tablets’ use.
Guess test to control efficacy of the blinding
At visit 2 (week 4 after TQD, ie, 5 weeks after treatment 
initiation) and at visit 5 (week 12 after TQD, ie, 13 weeks 
after treatment initiation), a guess test will be run. It 
consists of the following question:
Do you think you received:
 ► Placebo tablets and EC without nicotine? Yes/No
 ► Placebo tablets and EC with nicotine? Yes/No
 ► Varenicline (Champix) tablets and EC without nico-
tine? Yes/No
Concomitant care and interventions
All previously introduced medications will be permitted 
to be continued. The following concomitant medica-
tions per NRT’s licence in France, by extrapolation 
to nicotine-containing e-liquids and according to the 
requirement of the French drug agency (ANSM) will be 
prohibited: theophylline, clozapine, olanzapine, metha-
done, ropinirole, pharmaceutical caffeine (dose adapta-
tion when quit smoking).
As of today, varenicline has no known clinically signifi-
cant drug-drug interaction.
To the best of our knowledge, there is no available 
information about drug interaction of EC with or without 
nicotine.
NRT use is not permitted during the study but its over-
the-counter purchase cannot be controlled for. At each 
postquit day visit we will check its use as a control variable. 
Positive answer will result asking the participant to stop 
NRT use. If he/she does not comply, the participant will 
be excluded for non-compliance with the study protocol.
Primary outcome
Continuous smoking abstinence rate (CAR) (abstinence 
from conventional/combustible cigarettes) during the 
last 4 weeks (weeks 9–12) of the treatment period of 3 
months.
Definition: self-report of no smoking during the previous 
2 weeks and expired air CO ≤8 ppm. At visit 4 at week 
10 after TQD, that is, 11 weeks after treatment initiation 
AND at visit 5, week 12 after TQD, that is, 13 weeks after 
treatment initiation.
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secondary outcomes
 ► Safety profile of EC containing nicotine comparatively 
to its placebo and varenicline.
 ► Point prevalence abstinence: 7-day abstinence at visit 
1, 2, 3, 6 and 14 days of abstinence at visit 4 and 5 
(see timeline below) associated with expired air 
CO ≤8 ppm.
 ► Time to relapse to smoking after TQD.
 ► CAR confirmed by urinary anabasine 
concentration ≤3 ng/mL.
 ► Change in cigarettes/day consumption with respect 
of baseline.
 ► Change in craving for tobacco as assessed by the 
French 12-item Tobacco Craving Questionnaire34 with 
respect of baseline.
 ► Change in withdrawal symptoms as assessed by the 
modified Minnesota Nicotine Withdrawal Scale35 with 
respect of baseline.
Control variables
 ► Study medication compliance recorded at each visit.
 ► Baseline level of tobacco dependence.
 ► Urinary concentration of anabasine, anatabine (both 
alkaloids found only in tobacco, control for tobacco 
smoking) and cotinine (main metabolite of nicotine, 
control for nicotine intake) at visit 4 and 5.36 Anal-
ysis laboratory: Swiss Laboratory for Doping Analyses, 
Epalinges, Switzerland.
 ► Results of the ‘guess test’, that is, correct identifica-
tion of the treatments by participants.
Participant timeline
Randomisation visit=visit 0−dispensing of the treatment.
Treatment initiation within the 7 days following 
randomisation.
TQD should occur between 7 and 15 days after random-
ization and after 7 days of treatment intake (figure 1).
The first post-TQD visit (visit 1) is at week 2 after TQD, 
that is, 3 weeks after treatment initiation.
Visit 2 is at week 4 after TQD, that is, 5 weeks after treat-
ment initiation.
Visit 3 is at week 8 after TQD, that is, 9 weeks after treat-
ment initiation.
Visit 4 is at week 10 after TQD, that is, 11 weeks after 
treatment initiation.
Visit 5 is at week 12 after TQD, that is, 13 weeks after 
treatment initiation.
Visit 6 is at week 24 after TQD, that is, 25 weeks after 
treatment initiation.
Assessments at visit 0
Demographic characteristics
 ► Age
 ► Gender
 ► Professional situation
 – Employed/housewife/unemployed/student/
retired
 ► Education level: number of years after age 7 years
 ► Marital status
 – Cohabiting/married/separated/divorced/single/
widowed
 ► Annual household income (€)
 – <12 000/12 001–30 000/30 001–100 000/>100 000
 ► Self-reported ethnic origin
 – European/African/Asian/other.
Previous medical history:
 ► Any unstable disease condition within the last 3 
months defined by the investigator as major change 
in symptoms or treatments.
 ► Any life-threatening condition with life expectancy of 
<3 months.
 ► Alcohol use disorder defined as a score ≥10 on the 
AUDIT-C questionnaire.
 ► Abuse of or dependence on illegal drugs in the last 3 
months revealed by the medical history.
 ► Regular use of tobacco products other than cigarettes.
 ► Current or previous (last 6 months) use of EC.
 ► Pregnant women.
 ► Breastfeeding women.
 ► Current or past 3 months participation in another 
interventional research.
 ► Current or past (last 3 months) use of smoking cessa-
tion medication such as varenicline, bupropion, nico-
tine replacement therapies.
 ► Known lactose intolerance (placebo tablets contain 
lactose).
 ► Hypersensitivity to the active substance or to any of 
the excipients.
 ► Known severe renal failure.
Previous mental health history (before the last 6 months):
 ► Treatment for major depression.
Figure 1 The ECSMOKE trial’s outline.
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 ► Treatment for psychosis.
 ► Treatment for bipolar disorder.
 ► Treatment for substance use disorder.
 ► Cannabis, alcohol, cocaine, opioid, psychostimulant 
use.
 ► Treatment for smoking cessation by NRT, varenicline, 
bupropion.
Current, past 6 months, medical history:
 ► Cardiovascular disorders (yes/no); stable on treat-
ment: yes/no.
 ► Myocardial infarction/unstable angina (yes/no); 
stable on treatment: yes/no.
 ► Arterial hypertension (yes/no); stable on treatment: 
yes/no.
 ► Malignancy disorder (yes/no); stable on treatment: 
yes/no.
 ► Pulmonary disorder (other than COPD) (yes/no); 
stable on treatment: yes/no.
 ► COPD (yes/no); stable on treatment: yes/no.
 ► Type 1 or type 2 diabetes mellitus (yes/no); stable on 
treatment: yes/no.
 ► Other (yes/no); stable on treatment: yes/no.
Current, past 6 months, mental health history:
 ► Treatment for major depression (yes/no); stable on 
treatment: yes/no.
 ► Treatment for psychosis (yes/no); stable on treat-
ment: yes/no.
 ► Treatment for bipolar disorder (yes/no); stable on 
treatment: yes/no.
 ► Treatment for substance use disorder (yes/no).
 ► Cannabis, alcohol, cocaine, opioid, psychostimulant 
use disorder (exclusion if any).
 ► Treatment for smoking cessation by NRT, varenicline, 
bupropion (exclusion if any).
Smoking characteristics
 ► Age of the first cigarette (years).
 ► Age of regular smoking (years).
 ► Number of previous attempt(s) to quit.
 ► Longest duration of abstinence if any.
 ► Fagerström Test for Cigarette Dependence score.
 ► Spouse/partner smokes (yes/no).
 ► Other smoker in the household (yes/no).
 ► Secondhand smoke exposure at home/work/leisure 
(yes/no).
 ► Current self-reported number of cigarettes smoked 
per day.
Clinical measures
 ► Systolic and diastolic blood pressure in sitting position.
 ► Height.
 ► Body weight.
 ► Expired air CO along with time (minutes) since last 
cigarette smoked.
 ► Craving for tobacco using the French tobacco craving 
questionnaire (FTCQ)-12.34
 ► Withdrawal symptoms using the Minnesota Tobacco 
Withdrawal Scale (MNWS).35
Substance use
 ► Cannabis use in the last 30 days.
 ► Alcohol use.
The AUDIT will be used to screen for alcohol prob-
lems. It has been suggested as the most effective instru-
ment identifying individuals at-risk, hazardous or harmful 
drinking.37 Its sensitivity ranges from 51% to 97% and 
specificity from 78% to 96% according to a systematic 
review.38 The corresponding values for the CAGE ques-
tionnaire39 are: 43%–94% and 70%–97%.
The short French language form, AUDIT-C of the ques-
tionnaire will be used as recommended by recent French 
guidelines.40
At each visit will be measured
 ► Systolic and diastolic blood pressure in sitting position.
 ► Body weight.
 ► Cannabis use since the last visit.
 ► Alcohol use since the last visit (more than one drink 
per day/less than one drink per day).
 ► Expired air CO along with time since last cigarette.
 ► Current self-reported number of cigarette smoked 
per day in the last 7 days.
 ► Craving for tobacco using the FTCQ-12.34
 ► Withdrawal symptoms using the MNWS.35
Expired air CO will be measured with a Smokerlyzer 
(Bedfont Scientific, Kent, UK), a value of ≤8 ppm will be 
required to support the self-report of abstinence.
The FTCQ-12 and MNWS are paper and pencil self-re-
port questionnaires.
At each further visit adverse reactions/events are inquired 
with the following question:
"Did you experience since the last visit a health symptom 
or event which is unusual?"
If the answer is ‘yes’, the adverse reaction/event will be 
recorded.
sample size
According to the EAGLES study30 with n=8144 smokers, the 
per cent abstinent at the main efficacy criterion—similar 
to that used in the current study—was 33.5%. Taking this 
percentage as reference, with an OR=1/0.60=1.664 and a 
power of 80% we would need at least 272 participants in 
each of the varenicline (reference) and the ECwN group.41 
We would randomise one-third of the participants to the 
group ECwoN, that is 91 smokers. These numbers would 
allow to show a significant difference between varenicline 
and ECwN with an α=0.05. The total number needed to 
be randomised will, thus, be of 2×272+91=635 smokers. To 
take into account lost to follow-up, we plan to randomise 
at least 650 smokers: 280 in each of the ECwN and vareni-
cline arm and 90 (rounded) in the ECwoN arm.
Justification to randomise only 90 participants in the placebo-
placebo condition (ECwoN)
The main research question is the superiority of ECwN 
and varenicline (reference)—justifying of testing of 
non-inferiority between these groups including 280 
participants/group.
 o
n
 28 June 2019 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2018-028832 on 24 May 2019. Downloaded from 
8 Berlin I, et al. BMJ Open 2019;9:e028832. doi:10.1136/bmjopen-2018-028832
Open access 
If the superiority testing is non-significant, we propose 
to switch to non-inferiority testing.
We conclude on the non-inferiority if:
 ► ECwN is non-inferior to varenicline;
 ► ECwN is superior to ECwoN;
 ► Varenicline is superior to ECwoN.
Thus, the comparison involving ECwoN will be run 
‘after’ the comparisons between ECwN and varenicline.
We considered the following per cent of abstinence: 
p(varenicline)=33.5% and p(ECwoN)=15%. Thus, with 
280 participants in the varenicline and 90 participants 
in the ECwoN group, we will have sufficient power to 
conclude.
decision rules
We will conclude that ECwN is superior to varenicline if 
the two-tailed superiority test at 5% on the main outcome 
measure (percent abstinent (p)) will be significative such 
as p(ECwN)>p(varenicline).
Would this test show a p value >0.05, we would switch to 
non-inferiority. We will conclude that ECwN is non-infe-
rior to varenicline if:
 ► the two-tailed superiority test is non-significant at the 
5% level;
 ► the test of non-inferiority at 5% one-tailed with a 
delta=5% is significant;
 ► the two-tailed superiority test of p(ECwN) versus 
p(ECwoN) is significative at 5%;
 ► the two-tailed superiority test of p(varenicline) versus 
p(ECwoN) is significative at 5%.
In any case we will conclude that ECwN is superior to 
ECwoN, if the test of superiority at 5% (two-tailed) is 
significant such as p(ECwN)>p(ECwoN).
A Pearson’s two-tailed Χ2 test at 5% will be used to 
test the superiority. A Dunnet and Gent Χ2 test at 5%, 
one-tailed, will be used for testing the non-inferiority.42
Some simulations
If p(varenicline)=33.5%, p(ECwN)=33.5% and 
p(ECwoN)=15% then
1. the probability that ECwN is superior to varenicline is 
of 2.5%;
2. the probability that ECwN is non-inferior to vareni-
cline is of 31.5%;
3. the probability that ECwN is superior to varenicline is 
of 2.5%+31.5%=34%;
4. the probability that ECwN is superior to ECwoN is of 
95%.
If p(varenicline)=33.5%, p(ECwN)=40% and 
p(ECwoN)=15% then
1. the probability that ECwN is superior to varenicline is 
of 33.6%;
2. the probability that ECwN is non-inferior to vareni-
cline is of 52.7%;
3. the probability that ECwN is superior to varenicline is 
of 33.6%+52.7%=86.3%;
4. the probability that ECwN is superior to ECwoN is of 
99.8%.
If p(varenicline)=33.5%, p(ECwN)=45% and 
p(ECwoN)=15% then
1. the probability that ECwN is superior to varenicline is 
of 80.1%;
2. the probability that ECwN is non-inferior to vareni-
cline is of 19%;
3. the probability that ECwN is superior to varenicline is 
of 80.1%+19.0%=99.1%;
4. the probability that ECwN is superior to ECwoN is of 
99.9%.
The estimate of an abstinence rate of around 40% with 
the two active treatments and a 15% abstinence rate in 
the placebo condition seems reasonable and clinically 
significant.
There is no justification to run first a global compar-
ison. Either the ECwN arm is better than the varenicline 
arm and we have answered the main research question 
or the ECwN is non-inferior to the varenicline arm and 
there will be a necessity to run two separate comparisons 
against ECwoN (ie, ECwN against ECwoN; varenicline 
against ECwoN).
recruitment
Recruitment is either local (a) directly by the centres 
or centralised (b) using a web page and a centralised 
study-specific phone number and email address.
a. Smokers intending to quit smoking are recruited by 
advertisement in pharmacies, physicians’ offices situat-
ed in the catchment area of each investigator’s centre, 
by local newspapers and in public places of the cen-
tres’ healthcare facilities.
b. Candidates to participate can register by the study’s 
website, unique email address and phone number. 
Registration is followed by a phone screening before 
dispatching to the study centres.
Only one person by household will be recruited.
Assignment of interventions and blinding
To assure allocation concealment, computer-generated 
randomisation list (allocation ratio: 1:3:3) involving 
blocks, stratified by age (<45 vs ≥45 years) and centre, 
will be prepared and is kept blinded to all participants 
to the trial. The randomisation list is incorporated into 
the electronic Case Report Form (eCRF), and a treat-
ment number is attributed automatically on completion 
of the randomisation visit. The random, computer-gen-
erated allocation sequence is prepared by a statistician of 
the Clinical ResearchResearch Unit of Pitié Salpêtrière 
Charles Foix.
The randomisation list is being kept in a secured place 
by the sponsor and a copy of the randomisation code is 
being kept separately in the Poison Centre of Fernand 
Widal Hospital, Paris, in case of an SAE necessitating 
the opening of the participant’s group assignment (see 
below). Investigators, members of the coordination 
centre, hospital pharmacists and the sponsor’s clinical 
research assistants in charge of monitoring will be kept 
blinded.
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Blinding methods and measures to protect the blinding
Varenicline and its placebo are administered as non-iden-
tifiable tablets.
Because nicotine solutions tend to become yellow with 
time, the following provisions have been taken to make 
EC liquids non-identifiable:
Liquids of EC will be delivered to the participants in 
white, non-transparent vials of 10 mL specifically manu-
factured for the study. Both nicotine and no nicotine-con-
taining liquids will have a tobacco flavour and smell 
(blond tobacco). The EC’s clearomiser’ Pyrex walls will 
be transparent but of grey colour allowing the user to see 
the level of the liquid but not its colour.
Unblinding procedures
Unblinding is the sponsor’s decision. However, the inves-
tigating physician may request unblinding if he/she 
considers essential in the participant’s interest/care.
data collection and management
Data will be collected through the study’s eCRF. Data 
entry is carried out on electronic media via a web browser 
by co-investigators. The source documents are any orig-
inal document or item that proves the existence or accu-
racy of a data-point or fact recorded during the trial. 
Source documents are kept by the investigator, or by the 
hospital in the case of hospital medical records, for the 
statutory period. During and after the clinical study, all 
data collected about the study participants and sent to 
the sponsor by the investigators (or any other specialised 
collaborators) will be anonymised. CNIL, the French 
Data Protection Authority implemented the ‘Méthodol-
ogie de référence’ (MR-001) according to the provisions 
of Article 54, paragraph 5 of modified Law No. 78–17 of 6 
January 1978. The sponsor, Assitance publique-Hôpitaux 
de Paris has signed a commitment to comply with it.
dAtA AnALysIs
Populations submitted to the analyses
1. The ITT efficacy analysis will include all participants 
who were randomised and having received at least one 
dose of any study treatment.
2. Safety population: all participants who were randomised 
and having received at least one dose of any study treat-
ment.
3. Full analysis set population: all participants who were 
randomised and having received at least one dose of 
study treatment except those who had no data at all 
postrandomisation.
4. Per-protocol population: all participants who are fol-
lowed up to week 12 and for whom the main efficacy 
criterion (CAR week 9–12) is available and who re-
ceived at least one dose of treatment.
Handling of missing data
Participants who miss a visit will receive at least two phone 
calls as a reminder.
Missed visits are not a criterion for discontinuation. All 
participants will be strongly encouraged to stay in the trial 
up to the end of the research that is up to week 25.
Smoking (lapse: some puffs or relapse: relapse to 
regular conventional cigarette consumption) will not be 
a reason for discontinuation.
PrIMAry AnALysIs
We want to demonstrate the effectiveness of ECwN over 
varenicline. For that we will compare the percentage of 
success (CAR) between the two arms with a two-tailed 
Χ2 test. If this test is not significant (ie, p>5%), we will 
perform a non-inferiority test (switch) for ECwN over 
varenicline with a unilateral Dunnet and Gent test at 5% 
and a non-inferiority bound of ΔL=5%.
In parallel with the non-inferiority test, we will perform 
two tests of superiority, one comparing the ECwN with 
ECwoN on the one hand, and one comparing vareni-
cline with ECwoN on the other hand to ensure that the 
non-inferiority is not obtained by lack of efficacy in both 
ECwN and varenicline arms. Thus, non-inferiority will be 
achieved if the non-inferiority test is significant as well as 
the two superiority tests described above.
For the superiority tests, the analysis will focus on the 
ITT population and will be confirmed on the per protocol 
population. The non-inferiority test will be done on the 
per-protocol population and will be confirmed on the 
ITT population (see details in 'Decision rules' section).
sECondAry AnALysEs
Comparisons will be made between ECwN and vareni-
cline arms but may be done between the three treat-
ment arms. Qualitative variables will be analysed with 
a Χ2 test. Quantitative variables will be compared with 
Student’s t-test (or non-parametric tests as appropriate). 
Censored variables, such as the time to relapse will be 
analysed by the log rank test.
These three tests will be generalised with a logistic model, 
analysis of variance or a Cox model if adequate. Variables 
collected at different visits will be analysed in longitudinal, 
linear or logistic random effect models. In the same way, the 
absolute variation or the relative variation can be studied 
there also with linear models with random effect.
Missing secondary end points will be imputed in both ITT 
and per-protocol populations. The primary end point will 
be imputed by a multiple imputation method. The other 
criteria will not be imputed, since most of these criteria will 
be analysed in longitudinal analysis. We will perform a sensi-
tivity analysis by rerunning the population analysis of subjects 
whose primary end point is non-missing.
MonItorInG
Clinical Research Associates (CRAs) appointed by the 
sponsor are responsible for the proper running of 
the study, for collecting, documenting, recording and 
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reporting all handwritten data, in accordance with 
the Standard Operating Procedures applied within 
the Département de Recherche Clinique et d’Inno-
vation (DRCI) and in accordance with Good Clinical 
Practice as well as with the statutory and regulatory 
requirements.
The investigator and the members of the investigator's 
team agree to make themselves available during regular 
quality control visits by the CRA. During these visits, the 
following elements will be reviewed:
Written consent;
Compliance with the study protocol and its proce-
dures;
Quality of the data collected in the case report forms: 
accuracy, missing data, consistency of the data with 
the ‘source’ documents (medical files, appointment 
books, original copies of laboratory results, etc);
Management of the treatments used.
sAfEty AssEssMEnt
Safety will be assessed at each visit during the treat-
ment period. However, the safety assessment will also 
be conducted at visit 6 (end of research) even if no 
adverse event/reaction has previously been reported. 
Rational: one cannot exclude occurrence of adverse 
events/reactions even 3 months after stopping study 
medications.
safety end points
 AE diagnosis/description;
 The date when the AE started and stopped;
 Common Terminology Criteria for AdverseAdverse 
Events grade maximum intensity (https:// evs. nci. nih. 
gov/ ftp1/ CTCAE/ CTCAE_ 4. 03_ 2010- 06- 14_ Quick-
Reference_ 5x7. pdf)
 Whether the AE is serious or not;
 Reason why the SAE was serious (eg, hospitalisation);
 Investigator causality rating against the investigational 
product (yes or no);
 Action taken with regard to investigational product;
 Outcome.
Anticipated methods and timetable for measuring, collecting 
and analysing the safety end points
Safety and tolerance are recorded as follows:
AEs will be recorded in the ‘adverse event’ section of 
the case report form.
AEs declaration by the participant will be collected at 
each visit or anytime when the participant establish-
es a contact with his/her investigator. Investigators 
reports to the sponsor the participants’ declaration 
and/or examinations’ results linked to any adverse 
reaction/event along with its estimated severity and 
imputability. The Data Safety Monitoring Board 
(DSMB) will monitor safety data to avoid continuing 
the trial if it estimates that the risk prevails the ben-
efit.
recording and reporting adverse events
Definitions
Adverse event
Any untoward medical occurrence in a trial subject, which 
does not necessarily have a causal relationship with the 
clinical trial or with the investigational product.43
 ► Adverse reaction to an investigational medicinal product
Any AE occurred in a trial subject, which has a causal 
relationship with the clinical trial or with the investiga-
tional medicinal product.
 ► SAE or reaction
Any AE or reaction that at any dose of medication, 
results in death, threatens the life of the research subject, 
requires hospitalisation or prolongs hospitalisation, 
causes a severe or long-term disability or handicap or 
results in a congenital abnormality or deformity.
 ► Unexpected adverse reaction to an investigational medicinal 
product
Any adverse reaction to the product, whose nature, 
severity, frequency or outcome is inconsistent with the 
safety information described in the Reference Safety 
Information (summary of product characteristics, or the 
investigator's brochure if the product is not authorised).
 ► Emerging safety issue
Any new safety information that may lead to a reas-
sessment of the risk/benefit ratio of the trial or the 
investigational medicinal product, modifications in the 
investigational medicinal product use, the conduct of the 
clinical trial or the clinical trial documents, or a suspen-
sion, interruption or modification of the protocol of the 
clinical trial or other similar trials.
Examples:
a. Any clinically significant increase in the frequency of 
an expected serious adverse reaction.
b. Suspected unexpected serious adverse reactions in pa-
tients who have terminated their participation in the 
clinical trial that are notified by the investigator to the 
sponsor together with follow-up reports.
c. Any new safety issue relating to the conduct of the clin-
ical trial or the development of the investigational me-
dicinal product, that may impact the safety of the trial 
subjects.
d. Recommendations from the DSMB that may affect the 
safety of the trial subjects.
e. Any suspected unexpected serious adverse reaction 
reported to the sponsor by another sponsor of a trial 
carried out in a different country but relating to the 
same medication.
dAtA sAfEty MonItorInG boArd
A DSMB has been set up for this trial. Its primary mission 
is to serve as a committee for monitoring safety data. 
The sponsor is responsible for justifying the creation the 
DSMB to the Competent Authority (ANSM) and to the 
Ethics committee (CPP).
The DSMB’s preliminary meeting took place on 
12 December 2017, before the protocol submission 
 o
n
 28 June 2019 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2018-028832 on 24 May 2019. Downloaded from 
11Berlin I, et al. BMJ Open 2019;9:e028832. doi:10.1136/bmjopen-2018-028832
Open access
to competent health authority (ANSM) and Ethics 
committee (CPP). DSMB’s operating methods and the 
meeting schedule have been defined during this first 
meeting. All missions as well as the precise operating 
methods of the DSMB are described in the DSMB’s 
charter for the research.
The members of the DSMB are:
Pr Eric Bellissant, President, clinical pharmacologist 
with expertise in public health and social medicine, 
Centre Hospitalier Universitaire de Rennes, Rennes, 
France.
Pr. Daniel Thomas, cardiologist, previous head of the 
Department of Cardiology, Hôpitaux Universitaires 
Pitié-Salpêtrière, Paris, France.
Pr Laurence Galanti, physician, smoking cessation spe-
cialist, CHU Mont-Godinne, Belgium.
General information about the DSMB:
The DSMB makes recommendations to the sponsor 
about the continuation, modification or termination of 
the research. The recommendations that the DSMB can 
make are:
to continue the research with no modifications;
to continue the research with a modification to the 
protocol and/or to the monitoring of subjects;
to temporarily halt inclusions;
to permanently terminate the research in light of safe-
ty data: serious adverse events or reactions.
Ethics and dissemination
The potential participant is granted a reflection period 
of 1 week between the time when the subject receives 
the information and the time when he or she signs the 
consent form. Informed consent is obtained before the 
inclusion by the investigator physician as required for this 
type of study by French regulations. The form is available 
in French on request.
The persons responsible for the quality control of clin-
ical studies44 take all necessary precautions to ensure the 
confidentiality of information relating to the investiga-
tional medicinal products, the study, the study partici-
pants and in particular the identity of the participants 
and the results obtained. These persons, as well as the 
investigators themselves, are bound by professional 
secrecy.45 46
During and after the clinical study, all data collected 
about the study participants and sent to the sponsor by 
the investigators (or any other specialised collaborators) 
will be anonymised.
The principal investigator, the Unité de Recherche 
Clinique (Clinical Research Unit) and the sponsor will 
have access to the final trial dataset without limitation.
Investigators will communicate trial results to partici-
pants, health authorities, healthcare professionals, the 
public and other relevant groups without any publi-
cation restrictions. The Service Presse of Assistance 
publique-Hôpitaux de Paris will help prepare a dissemi-
nation plan to ensure results are accessible to the public.
Main authorship eligibility for publication in medical 
journals will follow International Committee of Medical 
Journal Editors criteria.47
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